/
/
A study for newly diagnosed high-risk multiple myeloma patients comparing combination therapies with or without the monocloncal antibody elotuzumab.
A study for newly diagnosed high-risk multiple myeloma patients comparing combination therapies with or without the monocloncal antibody elotuzumab. image
A study for newly diagnosed high-risk multiple myeloma patients comparing combination therapies with or without the monocloncal antibody elotuzumab.
Posted Dec 12, 2013

This is a clinical trial for newly diagnosed multiple myeloma patients that are considered to be high-risk. This Phase I/II study will determine if a new monoclonal antibody (a way of using your own immune system to kill myeloma) called elotuzumab makes existing combination therapies more effective. One half of the group will receive combination therapies of lenalidomide, bortezomib and dexamethasone (used regularly in standard myeloma care). The other half of the group will receive the same combination therapies (lenalidomide, bortezomib and dexamethasone) along with elotuzumab. These combination therapies are commonly used in therapy today. Lenalidomide and bortezomib may stop the growth of myeloma by blocking blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as elotuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Adding elotuzumab with chemotherapy may be a better way to block cancer growth. This study is looking to include 122 patients. For more details, learn more.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811